- Price
- $11.49
- Day
- -0.35%
- Mkt Cap
- $2.14B
- 52W Range
- $1.39 – $15.88
- Volume
- 14.61M
- Beta
- 2.52
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
Read full article
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS).
Read full article
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
Read full article
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read full article
Power Metallic Defines High-Grade Maiden Resource at Lion Averaging ~3.9% CuEq, with >85% Indicated and Significant Expansion Potential
Read full article
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
Read full article
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that three abstracts evaluating SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, in preclinical models of pancreatic ductal adenocarcinoma (PDAC) have been accepted for poster presentation at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
Read full article
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read full article